Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 18 Triple Negative Breast Neoplasms 3 Sarcoma 2 Neoplasm Metastasis 2 Refractory Solid Tumors 1 Metastatic HER2-positive Breast Cancer 1 Melanoma 1 Inoperable Locally Advanced HER2-Negative Breast Cancer 1 HER2-negative Breast Cancer 1 HER2-low Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Brain Neoplasms 1 Advanced Breast Cancer 1

Interventions

Fulvestrant 4 trastuzumab deruxtecan 2 elacestrant 2 Vinorelbine 2 AZD9833 2 toripalimab 1 talazoparib 1 ribociclib 1 pyrotinib 1 palbociclib 1 olaparib 1 exemestane 1 eribulin 1 disitamab vedotin 1 dalpiciclib 1 apatinib 1 abemaciclib 1 Selective Estrogen Receptor Modulators 1 Radiotherapy 1 RAD1901 1 Letrozole 1 Injections 1 Gonadotropin-Releasing Hormone 1 Everolimus 1 Capecitabine 1 Aromatase Inhibitors 1 Anastrozole 1 AZD5305 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Advanced Breast Cancer × eribulin × Clear all

NCT05530057 2025-11-20

ESPERO

Seoul National University Hospital

Phase 2 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡